Bestclinicabroad
Connect with the world's Best Clinic and doctors at Best Clinic Abroad. Your well-being is our priority, with personalized care every step of the way.
Connect with the world's Best Clinic and doctors at Best Clinic Abroad. Your well-being is our priority, with personalized care every step of the way.
8 Xishiku Ave, 西安门 Xicheng District, Beijing, China, 100034Peking University First Hospital has a total capacity of 1,805 beds across three campuses: Central, Miyun, and Daxing. The hospital delivers a full range of inpatient and outpatient services, serving patients across China and internationally.
Established in 1915, Peking University First Hospital (PUFH) is one of China's most prestigious medical institutions, affiliated with the Peking University Health Science Center. As a top-tier tertiary hospital classified as Grade 3A, it is recognized for its leadership in clinical excellence, education, and research. Over the decades, PUFH has been pioneering in shaping modern Chinese medicine, particularly in specialties such as urology, nephrology, pediatrics, neurology, cardiology, and organ transplantation.
The hospital is home to a team of highly qualified doctors and professors, including many national-level experts. Known for managing complex and rare diseases, it continues to advance patient care through innovation, multidisciplinary collaboration, and compassionate treatment.
Advanced Technology & Facilities
Key Services at Peking University First Hospital
Peking University First Hospital blends a century of medical heritage with high-quality clinical care, innovative research, and comprehensive education. It stands as a benchmark of excellence in China, committed to improving patient outcomes through multidisciplinary collaboration and compassionate, personalized care.
China, 2 Jiangtai Rd, ChaoyangThe hospital has approximately 50 inpatient beds in its main campus, along with nine satellite clinics across Beijing. It manages over 2,500 outpatient visits each week and provides care to hundreds of thousands of patients annually, both local and international.
Beijing United Family Hospital (BJU) is one of China’s most prestigious private medical institutions, known for delivering world-class healthcare that meets international standards. Established in 1997, it was the first foreign-invested hospital in China and has since become a trusted choice for both International and Chinese patients seeking high-quality, patient-focused care. As part of the United Family Healthcare network, BJU has built a reputation for medical excellence, advanced technology, and a uniquely personalized approach to treatment.
The hospital is staffed by a diverse team of internationally trained doctors, many of whom have practiced in top healthcare systems across the U.S., Europe, and Asia. This global expertise is complemented by the latest medical equipment, multilingual support services, and a strong commitment to clinical safety and patient satisfaction. Recognized by the Joint Commission International (JCI) for meeting the highest standards in healthcare delivery, BJU offers a full spectrum of medical services across numerous specialties, including family medicine, internal medicine, orthopedics, oncology, cardiology, obstetrics, pediatrics, and plastic surgery.
Advanced Technology & Facilities
Key Services at BJU
Beijing United Family Hospital stands as a pioneer in international-standard healthcare in China, blending modern technology, world-class medical expertise, and a warm, comprehensive approach to family health.
Suite 105, Wing 1, Kunsha Building No. 16 Xinyuanli, Chaoyang District, BeijingAs part of Singapore‑listed Raffles Medical Group, founded in 1976, RMG China operates 5 tertiary hospitals and over 100 clinics, supported by 430+ physicians and 900+ nurses & allied health professionals, delivering comprehensive inpatient and outpatient services.
Raffles Medical Group has operated in China since 2010, growing into a trusted name among both local and expatriate communities. All RMG China hospitals and clinics follow the Group’s Institutional Group Practice Model, which emphasizes integrated, peer-reviewed, and clinically audited care. Backed by Raffles Hospital Singapore, accredited by Joint Commission International (JCI), the network ensures alignment with global standards for quality and patient safety. With a rigorous clinical governance framework, strategic insurance and corporate partnerships, and a presence in key Chinese cities, RMG serves over 2.8 million patients annually. The Group continues to expand across China, offering world-class healthcare that combines international expertise with localized, patient-centered care.
Advanced Technology & Facilities
Key Services at Raffles Medical Group China
Raffles Medical Group China is a leading integrated private hospital network, delivering high-quality, multidisciplinary medical care in major Chinese cities. With its robust institutional infrastructure, advanced diagnostic and treatment facilities, and a reputation anchored by the Singapore-based Raffles Hospital, RMG China continues to expand and uphold global healthcare standards.
12th Floor, Lize SOHO South Tower, No. 20 Lize Road, Lize Financial Business District, Fengtai District, Beijing, ChinaGoBroad Healthcare Group, founded in 2017, is a leading medical network in China, specializing in the treatment of complex hematologic diseases and solid tumors. The group integrates clinical treatment, research, reference laboratories, and medical information technology under an Academic Research Organization model. With seven hospitals across Beijing, Shanghai, and Guangzhou, it provides advanced therapies including CAR-T cell therapy, hematopoietic stem cell transplantation, chemotherapy, radiotherapy, and targeted therapy. Its multidisciplinary teams ensure that patients receive comprehensive and personalized treatment for both common and rare conditions. The group is known for its patient-centered approach by combining modern medical science with innovative therapies and long-term follow-up care. With international collaborations, multilingual staff, and dedicated global patient services, it has become a trusted choice for individuals seeking specialized cancer and hematology treatments in China. By focusing on research-driven medicine, advanced facilities, and supportive care, GoBroad Healthcare Group continues to enhance patient survival, recovery, and long-term quality of life.
Advanced Technology & Facilities
Key Services
China’s healthcare system delivers cancer and blood disorder care within a nationally regulated medical framework overseen by the National Health Commission, where onco-hematology is treated as a highly specialized, hospital-based discipline. In recent years, China has continued to modernize cancer services through regulatory updates, expanded national cancer networks, and the structured adoption of advanced diagnostics and treatment planning systems. Large tertiary hospitals now commonly integrate molecular pathology, digital tumor boards, high-precision radiotherapy, and advanced hematology laboratories into routine onco-hematology care, reflecting a system designed around multidisciplinary evaluation and patient safety.
Physicians specializing in medical oncology and hematology in China complete a defined training pathway that includes a medical degree, standardized residency training, national licensing examinations, and subspecialty fellowship training in oncology, hematology, or related disciplines. Certification and scope of practice are regulated nationally, and continued licensure requires ongoing participation in continuing medical education and professional development. Many senior specialists hold academic positions at university-affiliated hospitals and participate in international research collaborations, clinical trials, and guideline development activities, supporting evidence-based practice and institutional accountability.
Hospital infrastructure for onco-hematology in China is primarily concentrated in large tertiary-care and academic medical centers. These hospitals are equipped with dedicated oncology wards, hematology units with protective isolation facilities, advanced imaging departments, radiation oncology suites, and intensive care units capable of managing complex medical needs. University affiliation is common and supports multidisciplinary collaboration among oncologists, hematologists, surgeons, radiologists, pathologists, and supportive care teams. Such infrastructure allows coordinated diagnostic evaluation, treatment planning, and monitoring within a single institution.
For foreign patients considering onco-hematology care in China, practical considerations are an important part of early planning. Most international patients require a valid visa to enter China, often supported by a medical invitation letter issued by the treating hospital. Cancer and blood disorder treatments frequently involve extended care timelines, and patients commonly plan for longer stays that may include several weeks or more, depending on treatment phases and monitoring requirements. Language barriers can arise, but many major hospitals maintain international patient departments that coordinate English-speaking staff or professional medical interpreters. Planning for follow-up care after returning home is often discussed early, with hospitals emphasizing the importance of complete treatment summaries, pathology reports, and medication documentation to support continuity of care.
In practice, patients typically begin exploring treatment options by reviewing hospital information or contacting international patient offices for general guidance. Hospitals often request comprehensive medical records for preliminary review, such as pathology reports, imaging studies, laboratory results, prior treatment summaries, and referral letters. Communication commonly takes place via email or secure digital platforms, where administrative teams help clarify documentation requirements, estimated timelines, consent processes, and non-clinical logistics. Patients and families frequently ask about length of stay, visa extensions, accommodation for caregivers, and coordination of care phases, reflecting the complexity of planning cancer treatment abroad rather than clinical decision-making itself.
Modern onco-hematology care in China reflects the structured adoption of advanced medical technologies and standardized clinical protocols aligned with international patient safety principles. Many tertiary centers utilize digital diagnostics, molecular and cytogenetic testing, next-generation sequencing panels, and high-resolution CT, MRI, and PET imaging to support accurate diagnosis and individualized treatment planning. Radiotherapy departments increasingly employ image-guided and intensity-modulated techniques, while hematology units rely on advanced laboratory systems for disease classification and monitoring.
Patient safety frameworks are reinforced through strict institutional protocols covering infection control, particularly in immunocompromised patients, diagnostic accuracy, imaging and radiation safety, and anesthesia oversight for interventional procedures. Hospitals implement multidisciplinary case reviews, formal informed consent processes, and structured post-treatment monitoring pathways. Supportive care services and follow-up schedules are integrated into care plans to ensure ongoing assessment during and after treatment phases.
Continuous professional development is an essential component of onco-hematology practice in China. Specialists regularly participate in continuing medical education programs, international oncology and hematology conferences, and collaborative research initiatives. Treatment plans are individualized, informed consent is mandatory, and all final clinical decisions depend on professional evaluation by licensed specialists within accredited institutions. At a national level, China continues to be recognized for its expanding regulatory oversight, research integration, and investment in safe, structured cancer care delivery.
Chemotherapy and other systemic therapies are used to manage a wide range of solid tumors and hematologic malignancies. In China, these treatments are typically administered in specialized oncology or hematology units with protocols governing drug preparation, dosing verification, and patient monitoring. Diagnostic planning commonly includes pathology confirmation and imaging studies, with safety oversight focused on infection prevention, infusion safety, and supportive monitoring.
Targeted therapy and immunotherapy are employed based on specific molecular or immunologic characteristics of a disease. Advanced laboratory testing supports treatment selection and monitoring. Clinical governance emphasizes diagnostic accuracy, management of therapy-related risks, and structured follow-up under specialist supervision, with functional objectives related to disease control and immune modulation.
Radiation oncology involves the use of precisely delivered radiation to treat cancerous tissues. Chinese cancer centers commonly use three-dimensional planning systems, CT-based simulation, and image-guided delivery techniques. Safety protocols address radiation dose planning, equipment calibration, and patient positioning, with oversight from multidisciplinary oncology teams.
Bone marrow and stem cell transplantation are used for selected hematologic conditions. These procedures are conducted in specialized transplant units with protective isolation and advanced laboratory support. Pre-transplant evaluation includes extensive diagnostic testing and donor matching, while clinical oversight emphasizes infection control, supportive care, and long-term monitoring.
Surgical oncology focuses on the removal or biopsy of tumors as part of cancer management. In China, these procedures are performed in tertiary hospitals with access to advanced imaging and pathology services. Safety protocols include anesthesia oversight, sterile technique, and postoperative monitoring, with functional objectives related to tumor management and diagnostic clarification.
Hematologic supportive care includes transfusion services, growth factor support, and management of blood-related complications. Diagnostic monitoring relies on advanced laboratory testing, and clinical governance emphasizes transfusion safety, documentation, and multidisciplinary oversight.
National Cancer Center China
Accreditations: National Health Commission oversight; national-level cancer center affiliation.
Specializations: This institution provides comprehensive oncology and hematology services, including medical oncology, radiation oncology, and hematologic malignancy care, within a multidisciplinary, research-focused environment.
Peking Union Medical College Hospital
Accreditations: National Health Commission oversight; Peking Union Medical College affiliation.
Specializations: The hospital offers advanced onco-hematology services, including complex diagnostics, systemic therapy, and supportive care, supported by academic research and multidisciplinary consultation.
Fudan University Shanghai Cancer Center
Accreditations: National Health Commission oversight; Fudan University affiliation.
Specializations: This center focuses on comprehensive cancer care, integrating medical oncology, hematology, radiation therapy, and clinical research within a tertiary-care framework.
Sun Yat-sen University Cancer Center
Accreditations: National Health Commission oversight; Sun Yat-sen University affiliation.
Specializations: The center delivers multidisciplinary oncology and hematology services, emphasizing advanced diagnostics, radiation oncology, and systemic therapy in an academic environment.
West China Hospital
Accreditations: National Health Commission oversight; Sichuan University affiliation.
Specializations: West China Hospital provides comprehensive onco-hematology services supported by advanced imaging, laboratory diagnostics, and multidisciplinary clinical teams.
Ruijin Hospital
Accreditations: National Health Commission oversight; Shanghai Jiao Tong University School of Medicine.
Specializations: Known for integrated oncology and hematology care, the hospital combines clinical services with academic research and structured patient safety systems.
China-Japan Friendship Hospital
Accreditations: National Health Commission oversight; national teaching hospital status.
Specializations: The hospital offers medical oncology and hematology services within a multidisciplinary framework emphasizing standardized protocols and international collaboration.
| Onco-Hematology Service | Estimated Cost Range (USD) |
| Chemotherapy (per cycle) | $1,500-$4,000 |
| Targeted Therapy (monthly) | $3,000-$8,000 |
| Radiation Therapy (full course) | $6,000-$15,000 |
| Bone Marrow Transplantation | $40,000-$90,000 |
| Diagnostic Biopsy and Pathology | $800-$3,000 |
| Advanced Molecular Testing | $1,000-$4,000 |
Note: The prices listed above are approximate, non-binding estimates provided for general informational purposes only. Actual treatment costs may vary based on individual clinical requirements, diagnostic findings, treatment complexity, materials or technology used, physician expertise, facility type, and duration of care. Final pricing is determined only after a professional evaluation by a licensed specialist or accredited medical institution.
China’s onco-hematology services are delivered within a centrally regulated healthcare system that emphasizes national oversight, institutional accountability, and standardized patient safety frameworks. The National Health Commission establishes requirements for hospital accreditation, specialist licensing, infection control, and clinical documentation. Large cancer centers implement internal audit systems, multidisciplinary review processes, and standardized consent pathways aligned with international clinical governance principles.
Specialist training standards require formal education, supervised clinical experience, and ongoing professional development. Many oncologists and hematologists participate in international conferences and research collaborations, supporting alignment with evidence-based medicine and evolving clinical guidelines. Advanced medical technologies-such as molecular diagnostics, precision radiotherapy, and digital health records-are increasingly integrated into routine care, supporting transparency and continuity.
China has also strengthened governance related to international patient services as part of broader medical tourism oversight. Public hospitals often maintain dedicated international offices that coordinate administrative processes, interpreter services, and documentation for foreign patients. Patients commonly seek reassurance regarding regulatory protection, data handling, and follow-up planning, and institutions typically address these concerns through formal, documented processes.
Restrictions and practical considerations:
Foreign patients may face visa-related limitations, extended treatment timelines requiring long stays, and regional differences in language support. Access to certain public hospital services may depend on institutional policies and capacity. Post-treatment monitoring and continuity of care after returning home require careful planning and comprehensive documentation, which hospitals generally emphasize during discharge planning.
Best Clinic Abroad is a medical travel facilitator, not a medical provider, and supports patients by helping them navigate non-clinical aspects of seeking complex care abroad. It does not provide diagnoses, treatment recommendations, or influence clinical decisions, which remain the responsibility of licensed oncologists, hematologists, and accredited hospitals. Its role focuses on coordination, information clarity, and administrative support.
➤ Hospital coordination - Support communication and coordination with accredited hospitals
➤ Appointment support - Assist with scheduling and organizing consultations
➤ Communication assistance - Help patients understand next steps without replacing medical advice
➤ Logistical guidance - Offer non-clinical support related to travel planning
All medical decisions are made exclusively by licensed physicians and accredited institutions, and patients who wish to better understand administrative processes may choose to engage with Best Clinic Abroad for guidance on next steps.
How does China treat cancer patients?
Cancer care in China is delivered through hospital-based oncology and hematology departments using a combination of systemic therapy, radiation, surgery, and supportive care. Treatment planning typically involves multidisciplinary evaluation, advanced diagnostics, and adherence to nationally regulated safety and clinical governance standards.
How expensive is cancer treatment in China?
The cost of cancer treatment in China varies widely depending on the type of cancer, treatment modality, and duration of care. Expenses can include diagnostics, therapy cycles, hospitalization, and supportive services, with final costs determined after professional clinical evaluation.
Can foreigners see doctors in China?
Yes, foreigners can see doctors in China at accredited hospitals and clinics. You generally need a valid visa, and many large hospitals offer international patient services with language support to help facilitate communication and administrative processes.
Disclaimer: This content is provided for informational purposes only and does not constitute medical advice. It reflects non-clinical observation of healthcare coordination processes and institutional practices in China and does not represent direct medical practice. Diagnosis and treatment decisions should always be made in consultation with a licensed medical specialist based on individual clinical evaluation.
Last updated: January 2026
.avif&w=3840&q=75)
